Streptavidin‐IL‐2 surface‐modified tumor cell vaccine could enhance the killing effect of specific antitumor T cells in RCC, but it could also induce high PD‐1 expression on these cells and upregulate PD‐L1 expression in TME. This evidence concerns the gene CD274 and renal cell carcinoma.